Clinical trials: TACE
Hepatocellular Carcinoma
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
The purpose of this study is to develop better ways to treat liver cancer, known as hepatocellular carcinoma or HCC, while it is still in the liver.
- Trial name
- NCT02513199
- Testing
- SBRT, TACE
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Uveal Melanoma
Tebentafusp-tebn With LDT in Metastatic UM
This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A*0201 positive patients with metastatic uveal melanoma.
- Trial name
- NCT06626516
- Testing
- Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Thomas Jefferson University
Liver Cancer
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
The purpose of the study is to find out the effects of using nivolumab with Drug Eluting Bead Transarterial Chemoembolization (deb-TACE) in the treatment of liver cancer.
- Trial name
- NCT03143270
- Testing
- Drug Eluting Bead Transarterial Chemoembolization, Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- TRACER (NCT01379521)
- Testing
- everolimus
- Where
- 5 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Hepatocellular
DCE-MRI for Assessment of Response to TACE of HCC
This study is conducted to evaluate dynamic contrast-enhanced MRI to quantify the efficacy of trans-arterial chemoembolization by comparing imaging results before and after treatment for at least one hepatic tumor and to look at…
- Trial name
- DCE-MRI (NCT02878109)
- Testing
- Post-treatment phase group, Pre-treatment phase group
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Hepatocellular Carcinoma
Randomized Phase II Trial of Chemoembolization and Sorafenib
The study will be a single-center, randomized Phase II study of conventional TACE in combination with sorafenib, given either continuously or sequentially, in patients with unresectable HCC.
- Trial name
- NCT02908165
- Testing
- conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
- Where
- United States
- Sponsor
- Yale University
Hepatocellular Carcinoma Non-resectable
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
Pivotal Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03533920
- Testing
- UNI-DEB
- Where
- 8 sites in South Korea
- Volunteers
- 62 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT02057874
- Testing
- 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary…
- Trial name
- NCT07368023
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the hypoxia caused by TACE in surviving tumor cell leads to release of angiogenic and growth factors contributing to…
- Conditions
- PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms, Carcinoma, Hepatocellular, Digestive System Neoplasms
- Trial name
- NCT01556815
- Testing
- Transarterial Chemoembolization (TACE), Sorafenib in combination with TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world and causes death of about 600000~1000000 people each year.
- Trial name
- SOON (NCT01997957)
- Testing
- S-1
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
HCC
Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy
This study is a prospective phase II, single arm clinical study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and…
- Trial name
- START-FIT (NCT03817736)
- Testing
- TACE, SBRT, Immune Checkpoint Inhibitor
- Where
- Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma Stage III
Prognostic Performance of Preoperative and Follow by Gadoxetic Enhanced MRI in HCC Patients After TACE
Interventional therapy is an effective alternative for patients with hepatocellular carcinoma (HCC) who are not indicated for surgery.
- Trial name
- NCT05125094
- Testing
- TACE,Ablation
- Volunteers
- 300 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma
The aim of this study is to compare the surgical outcomes of cytoreductive surgery followed by Transarterial Chemoembolization (TACE) with TACE alone in patients with MNHCC so as to establish a treatment standard for MNHCC.
- Trial name
- TACE (NCT00820157)
- Testing
- Cytoreductive Surgery, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group.
- Trial name
- NCT00820053
- Testing
- epirubicin and lipiodol
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignances seen in different regions of the world. The 5-year risk of recurrence of HCC after resection has been reported to be as high as 70%.
- Trial name
- NCT02253511
- Testing
- Cidan capsule
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zheng Donghai
Carcinoma, Hepatocellular
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
Vast majority of patients with hepatocellular carcinoma (HCC) present with unresectable disease. In the last decade results of randomized trials and a subsequent metaanalyses established transarterial chemoembolization (TACE) or…
- Trial name
- TACE-SBRT (NCT02794337)
- Testing
- SBRT, TACE, Sorafenib
- Where
- 2 sites in India
- Volunteers
- 67 people
- Sponsor
- Tata Memorial Hospital
Hepatocellular Carcinoma
Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation
Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered.
- Trial name
- CELPerCutCHC (NCT04813861)
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Central Hospital, Nancy, France
Hepatocellular Carcinoma Non-resectable
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab, transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX…
- Trial name
- NCT06904183
- Testing
- LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma
Pilot Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03564405
- Testing
- UNI-DEB
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.